The time frame would have to be uncertain because Juniper only had partial success after a lot of work. At least it was sufficient to enable some preliminary trials, but for the time and money spent, a big let down. Poor palatability restricts dosage, which restricts effectiveness, and therefore restricts full trial testing, so they're all interlinked, unfortunately.
Ann: Appendix 4C - Quarterly Report & Brief Company Update, page-29
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $83.14M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 21.5¢ | 21.0¢ | $102.7K | 480.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2380 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 230506 | 8 |
View Market Depth
| Last trade - 13.08pm 25/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |